ATOSIBAN Labatec conc perf 37.5 mg/5ml 5 ml
7680691850028
CH-69185
G02CX01
09.01.2.
1 / 3
google
Details
- Product number
- 6918502
- CPT
- -
- Packaging group
- 1
- Unit
- Durchstechflasche(n)
- Composition
- atosibanum 37.5 mg ut atosibani acetas 39.8 mg, mannitolum, acidum hydrochloridum, natrii hydroxidum corresp. natrium 4.8 mg, aqua ad iniectabile q.s. ad solutionem pro 5 ml.
Articles (1)
Atosiban Labatec 37.5 mg / 5 ml, solution à diluer pour perfusion
Lösung
1
Official Swissmedic V2 data
Additional information from the official database
Official medical documents
Detailed composition
| Substance | Quantity | Type | Category |
|---|---|---|---|
|
(N/A)
|
37.5 MG | Substance | Wirkstoff (Principe actif) |
|
(N/A)
|
39.8 MG | Substance | WIZUS |
|
(N/A)
|
- | Substance | HNIDK |
|
(N/A)
|
- | Substance | HNIDK |
|
(N/A)
|
- | Substance | HNIDK |
|
(N/A)
|
4.8 MG | Substance | HBESI |
|
(N/A)
|
- | Substance | HNIDK |
Authorization holder
Labatec Pharma SA
1217 Meyrin
Authorization information
- Swissmedic authorization number
- 69185
- Drug name
- Atosiban Labatec, solution injectable / solution à diluer pour perfusion
- Galenic form
- LSIN
- ATC Code
- G02CX01
- Authorization status
- Z
- Dispensation category
- B
- First authorization
- 04/03/2024
- Authorization expiration date
- 03/03/2029
- IT number
- 09.01.2.
- Domain
- Human medicine
Packaging details
- Description (FR)
- ATOSIBAN Labatec conc perf 37.5 mg/5ml 5 ml
- Description (DE)
- ATOSIBAN Labatec Inf Konz 37.5 mg/5ml 5 ml
- Market launch
- 04/03/2024
- Narcotic (BTM)
- No